Reactivating the phototransduction cascade with a mutation agnostic gene therapy preserves vision in rod-cone...

Area of Science:

• Ophthalmology
• Neuroscience
• Genetics

Background:

• Rod-cone dystrophy (RCD) is a group of inherited retinal diseases characterized by progressive vision loss due to photoreceptor degeneration.
• The disease typically begins with rod photoreceptor dysfunction, leading to secondary cone photoreceptor loss and severe visual impairment.

Purpose of the Study:

• To investigate the potential of reactivating degenerating cone photoreceptors in RCD.
• To explore the therapeutic efficacy of G-protein-coupled inwardly rectifying K (GIRK) channel expression for vision restoration in RCD.

Main Methods:

• Utilized two established mouse models of RCD to study the phototransduction cascade in degenerating cones.
• Employed adeno-associated viral vectors to deliver and express GIRK channels in cone photoreceptors.
• Examined human retinal tissue from late-stage RCD patients to assess cone-specific protein expression.

Main Results:

• Observed continued expression of opsin and arrestin in the cell bodies of degenerating cones in RCD mouse models.
• Demonstrated significant improvement in visual function in both RCD mouse models following GIRK channel gene therapy.
• Confirmed the presence of cone opsin and cone arrestin in human RCD patient retinas, indicating preserved molecular machinery.

Conclusions:

• Cone photoreceptors retain key molecular components even during degeneration in RCD.
• GIRK channel-based gene therapy presents a promising strategy for preserving or restoring visual function in RCD.
• This therapeutic approach holds potential for a wide range of RCD patients, irrespective of the underlying genetic cause.